Clinical research into Steinert disease (or myotonic dystrophy type 1 – DM1) is currently benefiting from a new positive impetus, in which France is playing a full part:
- Promising new results from the phase I/II ACHIEVE trial evaluating DYNE-101 have been announced in a press release. They confirm the trends presented in previous press releases, such as the improvement in muscle strength and the Myotonic Dystrophy Health Index (MDHI) score, and the reduction in myotonia. Recruitment of new participants is planned, including in France.
- Enrolment began in December 2024 for two new clinical trials, the HARBOR phase III trial evaluating AOC 1001 (Del-desiran) and the ArthemiR phase I/II trial evaluating ATX-01. Only a small number of pre-selected patients are expected to be enrolled in these two trials in France.
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1) – Dyne Therapeutics – 10 January 2025 press release
